Cargando...

Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure

Phosphodiesterase type 5 (PDE5) selectively hydrolyses the second messenger cGMP into 5′‐GMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP‐dependent pathway plays a significant role in various cardiovascular diseases. Therefore, its modulation by drugs, such as PDE5...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Pharmacol
Autores principales: Korkmaz‐Icöz, Sevil, Radovits, Tamás, Szabó, Gábor
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5758391/
https://ncbi.nlm.nih.gov/pubmed/28213937
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13749
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!